AstraZeneca PLC’s COVID-19 vaccine, which has been plagued with problems with its launch, may not even be needed in the United States, Dr. Anthony Fauci said Thursday. In an interview with Reuters, Fauci, director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to President Joe Biden, said that even if the AZN vaccine, -0.38% from AstraZeneca wins US regulatory approval. , The country may have enough vaccine doses. already insured to care for the entire US population, including potential drivers.
Asked by Reuters if he thinks the United States will use the AstraZeneca vaccine, Fauci said: “That is still up in the air. My general feeling is that given the contractual relationships we have with various companies, we have enough vaccines to meet all of our needs without invoking AstraZeneca. ” The US has already approved coronavirus vaccines from Pfizer Inc. PFE, + 0.19% and BioNTech SE BNTX, + 4.29%, Moderna Inc. MRNA, + 1.22% and Johnson & Johnson JNJ, -0.92%, and secured contracts for hundreds of millions of doses. Novavax NVAX, + 2.49%, which last year signed a $ 1.6 billion contract with the US government.As part of Operation Warp Speed, it hopes to obtain emergency use authorization for its vaccine from the Administration of Food and Drugs for May. That could leave AstraZeneca out as the strange drug maker. “If you look at the amount (of doses) that we are going to receive, the amount that you can get from J&J, from Novavax from Moderna if we hire more, we can probably handle any impulse that ‘I need, but I can’t say for sure’ Fauci said. If that happens, the United States may end up distributing its share of the AstraZeneca vaccine to other countries. Last month, the Biden administration announced that it would “loan” 4 million doses of the AstraZeneca vaccine to Canada and Mexico, which have already approved it. There has also been global pressure on rich countries to increase the number of vaccine doses to poorer countries. Last May, the United States obtained 300 million doses of the vaccine that AstraZeneca was developing. The AstraZeneca vaccine has been approved in more than 70 countries, but several European countries and Canada have suspended or restricted its use due to blood clotting problems. Confidence in the company also suffered when it was accused of selecting data on the vaccine’s effectiveness in a US study. Last week, the British drug maker updated that data, saying its vaccine was found to have 76% effective in preventing symptomatic COVID-19, up from the 79% previously announced.